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Abstract: The use and deployment of mobile devices across society is phenomenal with an increasing
number of individuals using mobile devices to track their everyday health. However, there is a
paucity of academic material examining this recent trend. Specifically, little is known about the use
and deployment of mobile heart monitoring devices for measuring palpitations and arrhythmia.
In this scoping literature review, we identify the contemporary evidence that reports the use of
mobile heart monitoring to assess palpitations and arrhythmia across populations. The review was
conducted between February and March 2018. Five electronic databases were searched: Association
for Computing Machinery (ACM), CINHAL, Google Scholar, PubMed, and Scopus. A total of 981
records were identified and, following the inclusion and exclusion criteria, nine papers formed the
final stage of the review. The results identified a total of six primary themes: purpose, environment,
population, wearable devices, assessment, and study design. A further 24 secondary themes were
identified across the primary themes. These included detection, cost effectiveness, recruitment, type of
setting, type of assessment, and commercial or purpose-built mobile device. This scoping review
highlights that further work is required to understand the impact of mobile heart monitoring devices
on how arrhythmias and palpitations are assessed and measured across all populations and ages of
society. A positive trend revealed by this review demonstrates how mobile heart monitoring devices
can support primary care providers to deliver high levels of care at a low cost to the service provider.
This has several benefits: alleviation of patient anxiety, lowering the risk of morbidity and mortality,
while progressively influencing national and international care pathway guidelines. Limitations of
this work include the paucity of knowledge and insight from primary care providers and lack of
qualitative material. We argue that future studies consider qualitative and mixed methods approaches
to complement quantitative methodologies and to ensure all actors’ experiences are recorded.
Keywords: cardiology; wearable devices; community care; primary care; technology; clinical care;
scoping review
1. Introduction
In the past two decades, there has been a phenomenal increase in the take-up of wearable mobile
devices, with many facilitating the measurement of a variety of health outputs. While many of
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these devices are basic, there are a number of devices that offer clinician-level diagnostic evaluations.
According to Public Health England (PHE), in the United Kingdom (UK), there are 1.4 million people
or 2.5% of the population who have atrial fibrillation (AF) [1]. Given the rise of these estimated
projections in addition to PHE purporting AF increases with age, in particular, with 80.5% of the English
population aged 65 years and over experiencing AF and a further 985,000 people living in England,
UK, with undiagnosed AF, equating to 425,000 people [1]. Moreover, there are global implications:
the United Nations (UN) estimate that there will 8.6 billion people by 2030, increasing to 9.8 billion in
2050 [2]. Consequently, there is an opportunity to determine whether mobile devices can provide a
timely and cost-effective solution to identify the risk of AF.
The purpose of this review is to explore the current trends in the use of wearable stand-alone
devices capable of recording the electrical activity of the heart electrocardiogram (ECG/EKG) used for
the detection of cardiac arrhythmias associated with palpitations.
People describe palpitations as a feeling that their heart is pounding or fluttering or that their
heartbeat is irregular [3,4]. These feelings can last from a few seconds to several minutes and patients
often perceive them as a serious cause for concern [3,4]. There are many reasons for palpitations
including changes in emotional or psychological state, the use of hormones, prescribed and illegal
drugs, excessive alcohol, smoking, strenuous exercise, and excessive consumption of caffeinated
drinks. In most cases, palpitations invariably raise a person’s anxiety, leading to increased visits to
their General Practitioner (GP) or hospital. Furthermore, it has been established that palpitations
are connected to greater morbidity, a higher risk of stroke, heart failure and an increase in risk of
mortality [5–9]. In the UK, the internationally recognised organisation “The Arrhythmia Alliance note
four out of 100 people aged ≥65 years are affected by AF one of the most common types of arrhythmia
(AR)” [3]. Patients present with varying symptoms including palpitations, shortness of breath or
chest pains. However, some people may not display any symptoms, but other indications will lead to
detection [3]. Repeated visits to the GP lead to the phenomenon of the ‘worried well’: patients who
may feel they are wasting health practitioners’ time and adding unnecessary costs on to the health
service. However, people’s quality of life (QOL) is severely affected by this health complaint. If AR is
suspected, the current recommended advice is to monitor a patient either in a hospital environment
or to wear a 24-h ECG device such as Holter monitor [3,4]. The recent development of substantially
cheaper wearable technologies provides a challenging alternative to the traditional approach.
Given the rise in ageing populations, a reduction in health care services and additional strains on
the delivery of primary care, there is a greater need to explore alternative, accurate and cost-effective
solutions to detect and diagnose AF. Mobile ECG devices are worth considering because they can
reduce the diagnosis time and have the potential to be cost effective, while enabling heart activity to be
monitored over a prolonged period [10]. By contrast, the traditional alternatives are uncomfortable
to use and can only be worn for a very limited amount of time or, in the case of implanted loop
recorders, they require invasive surgery [11]. Moreover, since 2010, wearable devices such as Fitbit
devices, Jawbone UP, Garmin Vivofit and Misfit Shine have increasingly been used to monitor and
analyse one’s daily activity through self-tracking users’ progress over time. Usually, goal-oriented [12]
tasks over a set period are agreed by the user (i.e., walk 10,000 steps per day). In addition, these
devices often offer rudimentary Heart Rate (monitoring). The user can then review their progress,
share their data with their friends, family and health practitioner (i.e., physician, nurse or consultant).
Contemporary evidence provides an insight into the use of mobile heart monitoring via wearable
devices to measure heart rate and rhythm [9,13–15]. Cheung, Krahn, and Andrade [9] discuss the
current and ongoing developments of wearable devices, which have entered the consumer market at a
phenomenal rate. Consequently, physiological data, sleep patterns, Heart Rate (HR) and much more
have been tracked. Cheung, Krahn and Andrade described the various wearable devices that have
the ability to track HR and AR [9]. Nonetheless, Cheung, Krahn and Andrade note that one of the
limitations of wearable devices is the level of accuracy, which has only been evaluated on small sample
sizes of patients presenting with unique symptoms [9]. Furthermore, Cheung, Krahn and Andrade
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argue that the suitability of wearable devices for detecting or for the treatment of AF within clinical
settings remains unanswered [9].
1.1. Overview of Mobile ECG Devices
There are several mobile ECG devices available on the market. Firstly, the HeartCheck™
ECG Pen [16] has received Food and Drug Administration (FDA) approval for monitoring AR.
The user/patient does not require a prescription to access/use the device and has Internet access
to a qualified physician. The HeartCheck™ device is easily transportable given the size of the
device—similar to a pen—and enables the user/patient to take their reading(s) anywhere [15].
Quinn et al. [17] conducted a clinical trial with the HeartCheck™ ECG Pen involving 22 primary
care clinics, 2054 participants aged 65 years and older (mean age = 73.7 ± 6.9). Participants had to
be attending clinics/appointments on a regular basis and were required to undertake three different
types of screening methods in the trial. The first screening method was a 30-s radial pulse check and
the second a single-lead ECG. The third consisted of a screening blood pressure machine with AF
detection. Participants who presented positively with one or more tests were then required to undergo
a 12-lead ECG with or without 24-h Holter. Participants with confirmed AF received a 90-day follow
up. The overall findings [16] showed the single-lead ECG and the blood pressure devices to have
superior specificity in comparison to the pulse check. Fifty-six (2.7%) participants were confirmed
with AF: 12 newly diagnosed and 44 previously diagnosed.
The EMAY mobile ECG device [18] is available to purchase from Amazon for £79.00. The company
states the device is ‘intended for initial evaluation’ and ‘not for medical diagnostic use’ [18]. The EMAY
device is used by both hands when taking a reading and can be used anytime and anywhere. The EMAY
website notes patients with a myriad of health conditions such as chronic disease, coronary heart
disease, diabetes, hypertension, myocarditis, obesity, chest pain, palpitations and dyspnea can use the
device [18]. Additional information on the EMAY website states several ‘cardiac situations that could
be detected’ that include missed beat, tachycardia, bradycardia, arrhythmia, Accidental Ventricular
Premature Beats (VPBs), VPB trigeminy, VPB bigeminy, VPB couple, VPB runs of 3, VPB runs of
4, VPB RonT, ST elevation, and ST depression [18]. To date the clinical trials website returned no
registered clinical trials using the EMAY mobile ECG device [19].
The Beurer ME 90 Bluetooth® mobile ECG device purports to accurately monitor and record
users/patients heart rhythm on the go, or at home. This device is compatible with iOS 8.0, Android 4.4,
Bluetooth 4.0 or above platforms. The device is categorised as a medical device and users/patients have
the ability to transfer recordings over Bluetooth. The Beurer ME 90 Bluetooth® has a USB portal and
has storage for 36 recordings. The device is CE marked and is covered by German health insurance
and pharmaceutical legislation [20]. To date, the clinical trials website returned no registered clinical
trials using the Beurer ME 90 Bluetooth®. The device is available to purchase from Amazon DE for
€137.72 or through a third party for approximately £134.55.
The AliveCor Kardia Mobile ECG device is available to purchase directly from the company
website or via other third-party websites for £99.00. The AliveCor device is available on both Android
and iOS platforms and it is noted the device should not be used with pacemakers or ICDs [21]. AliveCor
state that the device can detect AF instantly and is CE marked with positive National Institute for
Health Care Excellence (NICE) advice. AliveCor Kardia [21] declare the device has been clinically
proven and is used by leading cardiologists. Users/patients can track their weight and blood pressure
within one app and has the option to take unlimited EKG recordings. Users can take a recording in 30 s
using their thumbs pressing down on the pads. Users have additional options to pay for a premium
membership, which enables them to receive unlimited history and storage of EKG, and monthly reports.
To date, the company website reports a total of 69 peer-reviewed articles [22] using the AliveCor mobile
ECG device within a myriad of varying health cohorts and chronic diseases.
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1.2. Background Literature
Limited studies have examined how wearable devices perform compared to the Holter ECG.
For example, Pevnick et al.’s [23] retrospective paper explores existing wearable devices, which
have been designed specifically to measure activity, heart rate (HR) and heart rhythm. However,
this paper provides limited information and lacks critical insight into the deployment of mobile ECG
monitoring in primary care settings. Furthermore, it does not account for the perspective of health
practitioners, physicians, and cardiologists. Likewise, their proposed frameworks and taxonomies lack
clarity and theoretical underpinning, resulting in a paucity of in-depth knowledge and experience
of these devices. In the UK, the National Institute for Health Care Excellence (NICE) [10] provides
health information guidance, policy and practice, procedures, and standards. This guidance is
informed on evidenced-based studies for clinical practitioners, public health practitioners, and social
care institutions employed across the National Health Service (NHS). In 2015, The Newcastle and
York External Assessment Centre and the Medical Technologies Evaluation Programme, NICE [10],
conducted a literature search to identify evidence-based research and the cost effectiveness of the
AliveCor ECG device and the AliveECG App. A total of eight databases were searched, resulting in
1033 records retrieved. After screening, four papers were identified that met the review’s inclusion
criteria: Lau et al. [24], Lowres et al. [25], Haberman et al. [26] and Tarakji et al. [27]. The review
acknowledged that there were other mobile ECG devices available. For example, Dicare m1CC Colour
portable ECG recorder (Dimetek), MD100A ECG reader (Choice Medical), MD100E ECG reader (Choice
Medical), and HCG-801 ECG reader (Omron). Moreover, the review reported further information
from ‘Specialist commentator comments’ and the ‘Patient and carer perspective’ of The Arrhythmia
Alliance and the Atrial Fibrillation Association, respectively. While the commentary in the briefing can
be taken positively; it is unclear why the review focused specifically on the AliveCor ECG device and
the AliveECG app [22].
The Zenicor mobile ECG device was developed by the Swedish-based Zenicor Medical Systems
AB. [28]. The Zenicor ECG device enables readings to be taken by the user/patient by placing their
thumbs on two electrodes for 30 s. This device supports a web-based service that enables the analysis,
interpretation, presentation, and processing and storage of the ECG recordings, to the care provider.
The Zenicor ECG device is CE marked and is ISO (International Organization for Standardization)
13485 rated [29]. The Zenicor Medical Systems AB website lists three pieces of evidence-based research
(published in English) of the Zenicor mobile ECG device. These studies were conducted by Hendrikx
et al. [13], Usadel et al. [14], and Dahlqvist et al. [15]. Each used the Zenicor ECG mobile device
to explore AR. Both Hendrikx et al. [13], and Dahlqvist et al. [15] recruited participants aged 18≥
years. Usadel et al. [14] focused on AR in children aged between 5 and 17 years. Hendrikx et al. [13]
conducted a prospective, observation, cross-sectional study within a hospital’s clinical physiology
department. Hendrikx et al. [13] recruited 108 participants, who had been referred to clinicians for
ambiguous palpitations, or experiences of dizziness. In total, 95 patients (42 men and 53 women) were
assessed with a mean age of 54.1 years. All the participants were given a 24-h Holter ECG in addition
to the Zenicor EKG handheld (for 30 s). Readings were taken twice a day when the participants were
experiencing symptoms. The results from the 24-h Holter ECG ascertained two patients with AF and
a third with atrioventricular (AV), a further three patients displayed paroxysmal supraventricular
tachycardia (PSVT), and another patient presented with AV-block-II. Hendrikx et al. [13] concluded the
use and deployment of the Zenicor EKG handheld to be more effective than the 24-h Holter ECG in
detecting AF and PSVT, specifically with patients experiencing ambiguous symptoms.
The study by Usadel et al. [14] examined patients aged 0–17 years, who have or did not have
congenital heart defects, pacemaker/ICD or AF and compared a lead-12 ECG with the Zenicor EKG
handheld. Recordings and the transmission of data were completed successfully by the Zenicor EKG
device with thorough and consistent data readings. The P wave detection was reported to be challenging,
with 82 participants displaying heart rhythm disturbances. The detection of sensitivity via the Zenicor
EKG handheld identified 92% of participants diagnosed with supraventricular tachycardia, while
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abnormal ECGs were identified with 77 and 92% sensitivity and specificity, respectively. In conclusion,
Usadel et al. [14] noted that the use of the Zenicor EKG device with children was appropriate.
Moreover, they suggested that the device was a suitable tool for detecting and excluding tachycardia
in children. Dahlqvist et al. [15] evaluated the Zenicor EKG handheld to ascertain whether AF and
cardiac autonomic dysfunction can be diagnosed in children with univentricular hearts. A total of 27
patients were recruited and used the Zenicor EKG handheld over a period of 14 days, while a manual
AF analysis was conducted. The results from this study identified asymptomatic AF in one patient
while HRV was also identified in some patients. Dahlqvist et al. [15] concluded that the use of the
Zenicor EKG handheld device was a useful tool for detecting AF and cardiac autonomic dysfunction.
Reed et al. conducted a randomised control trial (RCT) [30] across multiple sites in the UK,
deploying the AliveCor ECG device to ascertain symptomatic rhythm detection in patients attending
the emergency department. Reed et al. [30] recruited 242 participants over a period of 18 months,
with 125 allocated to the intervention group and 117 to the control group. The findings from the RCT
were positive and the primary outcome of identifying symptomatic rhythm detection was identified in
69 participants in the intervention group, and 11 participants in the control group. The length of time
to identify the primary outcome was 9.5 days for those participants assigned to the intervention group
and 42.9 days for those participants assigned to the control group. Symptomatic cardia was detected
in 11 intervention group participants and in one person in the control group. During the RCT phase,
a total of seven questions were posed to participants assigned to the intervention group to ascertain
patient engagement and usability of the AliveCor ECG device. Overall, the results showed positive
responses to engaging and using the ECG device. The majority of participants (70%) reported to have
never using a mobile ECG device; 21.6% of participants strongly agreed that the AliveCor ECG device
will be useful in diagnosing their symptoms; 22.4% reported positively to recording their heart tracing
based on their initial experiences upon entering the emergency department. Furthermore, 28.0% of
participants reported having no problems or concerns when they sent a heart trace to the study team,
while 32.0% of participants strongly agreed with having no problems recording a trace. Reed et al. [30]
reported that their study demonstrated the cost benefits of using the AliveCor ECG device relating to
primary, community and secondary care for both the intervention and control groups. The authors
identified a £108 cost saving for participants in the intervention group. While no cost saving was
identified for the control group, further analysis found that the cost saving per symptomatic rhythm
diagnosis was less per patient in the intervention group (£474) compared to the control group (£1395).
Reed et al. [30] argue that their findings are generalizable from emergency medicine to general practice,
across a myriad of health care systems. However, Reed et al. [30] study reported findings based on
the use and deployment of one particular ECG device. While they did not state the justification(s)
for choosing the AliveCor ECG device over other devices available on the market, the results have
demonstrated the positive effects of using a mobile ECG device.
Acknowledging the growing popularity of mobile heart monitoring (including ECG) devices,
a search of the clinicaltrials.gov website [31] was undertaken. The website displays information
concerning clinical trials that are either completed, active, recruiting, not recruiting or unknown.
Three individual searches were conducted using the search terms ‘Alivecor [32] ECG device’, ‘Zenicor
ECG device’ and ‘atrial fibrillation and wearable devices’. The device terms were used because of
the studies referred to earlier. The latter term was used to capture any other device(s). Regarding
the Alivecor [32] ECG device, 25 registered trials between the years 2013 and 2019 were identified.
The majority of the 25 studies were conducted in the USA (n = 17). The remainder were conducted in
Canada (n = 2), Hong Kong (n = 2), UK (n = 1), Belgium (n = 1), India (n = 1), and the Netherlands
(n = 1). Five trials between 2012 and 2019 were identified involving the Zenicor ECG device [33].
The majority had been conducted in Sweden (n = 3), but also included one in Germany (n = 1) and one
conducted in multiple locations (Denmark, Sweden and Austria). The final search using the terms
‘atrial fibrillation and wearable devices’ (e.g., Garmin Smart Watch, Amiigo Watch and Wristband,
and iRhythm Zio XT Patch) yielded a further 17 trials between 2012 and 2019 [34]. Five trials were
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conducted in the USA (n = 5), two in Canada (n = 2), two in Finland (n = 2), two in Israel (n = 2),
and one each in Belgium (n = 1), China (n = 1), Germany/Switzerland (n = 1) Singapore (n = 1), Spain
(n = 1) and in the UK (n = 1), respectively. The HeartCheck™ device was used in one RCT study
conducted in Canada [35].
Although this complex and rapidly changing field represents an attractive prospect for the
diagnosis of heart and circulatory disease, there are few reviews that look at mobile self-monitoring
ECG devices designed to diagnose cardiac arrhythmia that coincide with cardiac event-related
conditions such as palpitations. This paper reviews the contemporary literature and examines whether
the evidence obtained from studies with such devices can support primary care providers to deliver
high levels of care at a low cost to the service provider. Although the causes of palpitations are variable,
they are occasionally a manifestation of potentially life-threatening arrhythmia (AR). Under conditions
where abnormal heart rhythms and cardiac symptoms are irregular and infrequent, such mobile
self-monitoring ECG devices have potential as event monitors during symptoms such as palpitations.
Cheung, Krahn, and Andrade [9] argued that one of the limitations of wearable device studies was
their reliance on small sample sizes involving patients presenting with unique symptoms.
This review is distinctive and timely in that it provides an insight into an increasingly complex
field that combines the precision demanded by the medical profession with wearable technology
that has advanced rapidly with the development of miniaturised, and increasingly accurate, sensors.
The authors believe it is the first review of its kind to explore contemporary evidence surrounding the
use of mobile ECG devices and, consequently, contributes to the field of primary care and medicine.
The authors aim to offer further evidence for the support of such devices in a community setting and
to answer the question of what contemporary evidence reports the use of mobile ECG monitoring to
assess palpitations that occur with AR across populations.
2. Methods
A scoping review strategy was selected to chart this important and complex subject. Arksey
and O’Malley [36] propose that scoping reviews provide a clear and thorough method for providing
an overview of significant and quickly developing areas of research. Furthermore, Arksey and
O’Malley [36] note the aim of this type of review is ‘to illustrate the field of interest in terms of the
volume, nature and characteristics of the primary research’ (p. 30).
In order to chart the emerging nature of the rapidly developing area of mobile heart measuring
devices, a scoping review was deployed using Arksey and O’Malley’s [36] framework. This framework
gives both an overview of the topic and facilitates an examination of the breadth and depth of
knowledge of the subject. One of the framework’s strengths is that it allows the authors to draw
conclusions about the overall state of research activity and make recommendations for future research.
2.1. Objectives
This review was guided by Arksey and O’Malley’s five-stage framework [36], which includes (a)
establishing the research question, (b) the identification of pertinent studies, (c) the choice of studies,
(d) mapping the data and (e) collating, summarizing and reporting the findings.
2.2. Search Strategy
The search strategy consisted of a systematic search of five electronic databases. The databases
examined were the Association for Computing Machinery (ACM, New York, NY, USA), CINHAL,
Google Scholar, PubMed, and Scopus. The date criterion of the search was for material published
between January 2010 and February 2018. The search was conducted between February and March 2018.
Each database underwent individual search strategies and the limiters were ‘English’ and ‘humans’.
Articles, their references (BibTeX format) and, where possible, the CSV files were exported into Dropbox
and Mendeley. An inclusion and exclusion criteria were developed and deployed. The complete search
criteria are given in Table 1.
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Table 1. Criteria for study selection.
Inclusion Exclusion
Mobile apps (mApps) Master’s and PhD thesis
Electrocardiogram (ECG/EKG) Conference proceedings
Cardiogram Book Chapters
Wearables Reports
Atrial Fibrillation (AF) Reviews
Heart Pulse monitoring
Human Theoretical papers
ECG Wearable Devices/Patches Athletes
Mobile Health (mHealth) Defibrillators
Security/Privacy Intensive care unit (ICU) or highdependency unit (HDU)
Smart Fabric/textiles WSBN
Papers published in Journals Animals/non-human
Commercial technologies Co-morbidities (i.e., transplant patients)
Purpose-built technologies Newsletters
Encryption Editorials
Big Data PhD, MSc & BSc Thesis
Human
Study designs: (randomised control trial (RCT),
Exploratory, Cohort, Prospective, Feasibility)
2.3. Selection Criteria
Studies were included if they met the inclusion criteria (Table 1). Titles of papers and abstracts
were initially screened for suitability and, where necessary, the full paper was then reviewed. The final
decision was determined by two authors (H.M. and D.B.). Both H.M. and D.B. reviewed all articles
from each database separately and then collectively. Where additional discrepancies were highlighted,
H.M. and D.B. reviewed and discussed the respective paper(s) before a final decision was made.
Both abstracts and full texts were retrieved to determine whether they met the inclusion/exclusion
criteria. Both H.M. and D.B. jointly decided the final selection of papers for inclusion.
3. Results
The initial search yielded 981 records across the five databases. However, 11 records were
not available (six from CINHAL and five from Google Scholar). Consequently, 970 records were
accessed, and 112 duplicates removed. The remaining 858 records were then judged against the
inclusion/exclusion criteria (see Table 1). Subsequently, 800 records failed the inclusion criteria and
were excluded from the review. The remaining 58 papers were subjected to a full text assessment and a
further 49 papers were excluded (Figure 1). Nine papers met the inclusion criteria of the review.
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3.1. General Characteristics of Studies
Analysis of the final nine articles found that they were all published between 2015 and 2017 and
the majority were located in the PubMed database (n = 5). The sample size varied across all articles
from 25,415 participants in the study published by Arronsson et al. [37] to 22 participants in the study
published by Doliwa et al. [38]. The total sample includes 27,346 participants with a mean age of
57.18 ± 7.42, and the median age is 64.45. Five studies reported the percentage or number of female
participants [37–42], while three studies recruited only male participants [26,43,44]. Three studies
were performed in Europe: Arronsson et al. [37], Doliwa, Rosenqvist and Frykman [38], and Halcox
et al. [42]. Five studies were conducted in the USA: Boudreaux et al. [39], Turakhia et al. [44], Haberman
et al. [26], Hickey and Freedson [41] and McManus et al. [43]. The remaining study was conducted in
Africa by Evans et al. [40]. Study design varied, with three studies reporting an observation cohort
study Arronsson et al. [37], Halcox et al. [42], Haberman et al. [26]. Two studies reported on an
experimental study approach: Evans et al. [40] and McManus et al. [43]. Hickey and Freedson [41]
reported an experimental comparative study design. A further two studies reported a prospective
observation study design: Boudreaux et al. [39] and Halcox et al. [42]. One study, Doliwa, Rosenqvist
and Frykman, reported an experimental RCT design [38].
3.2. Themes
A total of six primary themes and the 24 secondary themes which were identified through the
review process. The secondary themes detail the type of assessments used in the studies.
3.3. Primary Themes
A total of six primary themes (purpose and objectives, environment, population, wearable devices,
assessment, and study design) were identified and are explained in the proceeding sections.
The purpose and objectives theme comprised five secondary themes: detection, feasibility,
comparison, cost effectiveness and study protocol. The Halcox et al. [42] study does not directly report
the purpose of the study. However, critical examination of the complete paper revealed, that Halcox
et al. [42] compared the AliveCor device with the delivery of routine care [42].
Four studies, Arronsson et al. [37]; Boudreaux et al. [39]; Turakhia et al. [44] and McManus
et al. [43] used the detection of AF to assess the ECG device. Evans et al. [40] explored the feasibility
of the AliveCor ECG device. The study by Boudreaux et al. [39] compared the energy expenditure
(EE) during a particular activity (i.e., resistance training). Haberman et al. [26], and Doliwa et al. [38]
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compared the AliveCor mobile ECG device against the traditional method of a 12-lead ECG. Cost
effectiveness (CE) was also assessed by Arronsson et al. [37]. We have included the McManus et
al. study protocol that outlines a single-centre, prospective randomised control trial (RCT) that
deployed the AliveCor ECG device over a 30-day period [43]. This study protocol reported three
aims: (a) to document AF using real-time ECG capture; (b) to evaluate the impact on AF treatment
and Quality-Adjusted Life Years (QALYs—A generic measure of disease burden); and (c) to evaluate
the effectiveness of text messaging on AF knowledge and proactive self-management of multiple
chronic conditions.
The environment theme highlighted the different types of environment where studies were
undertaken. Four secondary themes were identified: multiple screening centres, university/laboratory,
rural community/hospital and a Veteran Affairs centre. The Aronsson et al. [37] study was located
in multiple screening centres (n = 6) as reported in their earlier publication by Friberg et al. [45].
Five studies took place in university/laboratory settings Boudreaux et al. [39], Halcox et al. [42],
Haberman et al. [26], McManus et al. [43], and Hickey et al. [41]. One study by Doliwa, Rosenqvist and
Frykman was conducted in a hospital setting [38]. The study by Evans et al. [40] took place in a rural
community/hospital where cardiology resources were limited. Moreover, there was only one 12-lead
ECG tape available. The Turakhia et al. [44] study was conducted at the Veteran Affairs (VA) Palo Alto
Health Care System.
The population theme encompasses three secondary themes: recruitment, sample, and sample size.
Across all the studies, the nature of recruitment varied and included hospital clinics by Halcox et al. [42],
the recruitment of veterans by Turakhia et al. [44], specific cardiology clinics/departments by Evans
et al. [40], Haberman et al. [26], and McManus et al. [42], and university students by Haberman
et al. [26]. The sample also varied and included older adults [44], athletes [26], healthy adults [26]
and those with existing comorbidities (i.e., coronary disease, heart failure) [26]. The size of samples
ranged from Aronsson et al. [37]’s 25,415 participants [37] to Doliwa, Rosenqvist, and Frykman’s 22
participants [38]. Boudreaux et al. [39] recruited participants aged between 18 and 35 years, while
Aronsson et al. [37] primarily recruited adults aged between 75 and 76 years. The majority of studies
recruited participants of both genders with the exception of Turakhia et al. [44] who recruited only
male participants.
The wearable devices theme encompassed three secondary themes: commercial, wearable patch
and purpose-built devices. Eight studies utilised commercial devices. Two studies used the Zenicor
ECG device: Aronsson et al. [37], and Doliwa, Rosenqvist, and Frykman [38]. One study by Boudreaux
et al. [39] used multiple heart rate measuring mobile devices (i.e., Apple Watch Series 2, Fitbit Blaze,
Fitbit Charge 2, Polar H7, Polar A360, Garmin Vivosmart HR, TomTom Touch, and Bose SoundSport
Pulse headphones). Five studies—Evans et al. [40] Halcox et al. [42] Haberman et al. [26], Hickey and
Freedson, [41] and McManus et al. [43]—Used the AliveCor Kardia mobile device, which is attached to
an Apple iPhone. One study, Turakhia et al. [44], deployed the Zio wearable patch that sits against
chest skin. Finally, McManus et al. [43] used a purpose-built mobile app (mApp) called PULSE-SMART
to undertake participants ECG readings and that was connected to an Apple iPhone 4S.
The assessment theme encapsulates 11 secondary themes: the completion of assessment (i.e., health
practitioner); self-assessment surveys—non-validated (health—anxiety, perceived benefits from health
care practitioners), qualitative data (i.e., patient diary of symptoms); AF scales for the Assessment,
Medication Assessment, Other Assessment, Quality of Life, Anxiety Scale; Technology-based
Assessment and ECG monitoring (Holter or Mobile device) and patient health medical records
(demographics, medical history, health behaviours). Due to the number of themes, this section only
states theme type and one respective study. The completion of assessment by a health practitioner:
Evans et al. [40]. Self-assessment surveys—non validated (health—anxiety, perceived benefits from
health care practitioners): Doliwa et al. [38]. Qualitative data (i.e., patient diary of symptoms):
Turakhia et al. [44]. AF scales for Assessment: Hickey et al. [41]. Medication Assessment, Other
Assessment: Hickey et al. [41]. Quality of Life: McManus et al. [43]. Anxiety Scale: Hickey et al. [41].
Healthcare 2019, 7, 96 10 of 23
Technology-based Assessment and ECG monitoring (Holter or Mobile device): Halcox et al. [42]. Finally,
patient health medical records (demographics, medical history, health behaviours): Turakhia et al. [44].
The study that utilised the majority of assessments was that undertaken by Hickey and
Freedson [41]. Hickey and Freedson [41] used 10 instruments (n = 10) in conjunction with
baseline and monthly data recording (via electronic medical records system review) throughout
the six-month duration of the study. The 10 assessments deployed were: the Atrial Fibrillation
Knowledge Scale (AFKS) [46]; the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale
(CCS-SAF) [47]; the Atrial Fibrillation Effect on Quality of Life (AFEQT) [48]; the Control Attitudes
Scale-Revised (CAS-R) [49]; the Morisky 4-item Self-Report Measure of Medication-Taking Behaviour
(MMAS-4) [50,51]; the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) [52]; the Short Form
Health Survey (SF-36 Quality of Life) [53,54]; European Questionnaire 5 Dimensions (EQ-5D) [55,56];
the Patient Health Questionnaire (PHQ-9) [57]; and the State Trait Anxiety Inventory (STAI) [58].
The study design theme encompasses three secondary themes: duration, study criteria,
and study type. Across the studies (depending upon the study design), some studies required
their patients/participants to provided additional information in conjunction to their respective mobile
ECG reading. Readings were taken over various times in the respective studies. Halcox et al. [42]
measured twice per week for 12 months, while Hickey and Freedson [41] recorded three times per
week over a six-month period. Aronsson et al. [37], Evans et al. [40], Turakhia et al. [44], used a
two-week period. Doliwa, Rosenqvist, and Frykman [38] patients used the Zenicor ECG device over a
30-day period while McManus et al. [43] used a 2-min waveform reading. Five studies stated that
their study design included study criteria (i.e., inclusion/exclusion). For example, Doliwa, Rosenqvist,
and Frykman [38] recruited 22-participants with a diagnosis of symptomatic paroxysmal AF. While
Haberman et al. [26] recruited 335 participants from Division I athletes, healthy young adults, and
cardiology clinics. Hickey and Freedson [41] recruited adults >18 years, who had a 30-day history
of AF, were either male or female, able to use a smartphone, and participants who were able to read
and receive text messages on the day of enrolment onto the study. Furthermore, Turakhia et al. [44]
recruited participants from cardiology, echocardiography and stress-testing clinics with additional
inclusion criteria of specific age and having a minimum of two risk factors. The exclusion criteria
included prior AF diagnoses, stroke, transient ischemic attacks, implantable pacemaker or defibrillator
or someone who experienced palpitations or syncope in the previous year [44]. The McManus et al. [43]
study was the one investigation aimed at testing a hypothesis using a prototype which measured
waveforms via the iPhone 4S. Across all selected studies, each one reported a different study type (i.e.,
RCT or comparative). None of the nine studies reported the same study design.
4. Discussion
Principle Findings
This review paper provides a contemporary insight into the growing field of mobile ECG
monitoring and detecting AF that coincides with palpitations. Out of 981 abstracts, a total of nine
papers were selected for a comprehensive examination. A total of six primary themes were identified
and, within each primary theme, a series of secondary themes were ascertained. Given the increasing
use of wearable devices coupled with the increase in ageing populations and the drive to provide
cost-effective primary care, the evidence lends itself to the adoption of mobile ECG monitoring into
care practice and policy. As stated earlier in this paper, NICE [10] in the UK are primarily using the
AliveCor Kardia ECG device.
The primary themes, environment and population, highlight the range of research centres,
laboratories, and geographic locations that have investigated ECG mobile devices. Nonetheless,
there is an argument that these selected studies are community based. However, the participants are
not reported to have been recruited through a physician, surgery, or from a hospital via a cardiologist.
The theme of population highlighted the varying sample sizes and how, in some instances, participants
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were recruited through cardiology clinics or departments; nevertheless, this was limited to three
studies. Overall, the age range of participants illustrated a spread across populations; ensuring patients
of all ages who presented with palpitations were involved in the studies. The primary theme wearable
devices encompassed commercial, wearable, and purpose-built technology as a means of detecting
and measuring AR and AF during periods when palpitations are prevalent. Overall, four studies
used the AliveCor Kardia device, accessible via the Apple iPhone, while two studies deployed the
commercial ECG device Zenicor. To date, there have only been a handful of studies published in
academic journals [13–15], or via the Zenicor website [59] that examine purpose-built or commercial
ECG devices.
With the exception of Evans et al. [40], no other selected study provided an insight into the use
of mobile ECG devices and monitoring from the perspective of health practitioners. The final nine
selected papers provide insights into the varying rationales for monitoring palpitations and AR across
populations. We suggest that undertaking a community-based approach that included a physician
(s) or consultant cardiologist would offer greater insights into the benefits of mobile ECG monitoring
from the viewpoint of both health practitioner and providers.
All nine studies used an assortment of assessments and measures, which formed 11 secondary
themes. The assessment theme indicates the complexity of deploying mobile ECG devices in conjunction
with additional health outcomes to ascertain patient’s levels of anxiety, quality of life, and the detection
of AF through self-reporting and/or clinical practitioners. Varying study designs were executed.
Nonetheless, given the limited duration of assessment, the results showed a positive trend in detecting
AF. While AF and AR may vary across populations, the studies did report that patient response via the
technology occurred at the time of the patient experiencing palpitations. Furthermore, the objectives
of the studies also varied and ranged from validation to feasibility, cost effectiveness and clinical
trials. This is further evidenced by the increase in clinical trials, as noted in this review’s introduction.
Consequently, the many clinical trials at various stages across the world highlight the widespread
interest in this application of mobile health technology. However, drawing comparisons across the
selected studies is problematic based upon the varying environments, assessments, populations,
and wearable devices. While the cost effectiveness is a principal concern for primary care and
health care strategists, preliminary evidence from this review (Table 2), coupled with findings from
recent international studies such as Hendrikx et al. [13], Usadel et al. [14] and Dahlqvist et al. [15],
demonstrates the great potential of deploying wearable ECG devices.
Table 2. Databases searched, search terms used, and adaptations employed.
Database Search Term Used Adaptions
Association for
Computing Machinery
(ACM)
(Arrhythmia Atrial Fibrillation ECG EKG Palpitations
wearables) AND (-Algorithms -map -sensor -consumer
-mathematical -statistical) AND keywords. author.
keyword:(Arrhythmia Atrial Fibrillation ECG EKG
Palpitations wearables -wavelet -brain -skin -posture
-music -grasp -grip -sonic -speculative) AND record
Abstract: (Arrhythmia Atrial Fibrillation ECG EKG
Palpitations wearables)
Manufacturers’/generic names not
recognised. NOT any: Algorithms
map sensor consumer
mathematical statistical. Keyword
NOT: wavelet brain skin posture
music grasp grip sonic
CINHAL
(TX (“Palpitations” OR “Arrhythmia” OR “Atrial
Fibrillation”)) AND (TX “Wearable ECG”) AND (TX
“Wearable EKG”) OR (TX (“Wearable technologies” OR
Wearable devices)) NOT (TX (“Catheter” OR “Surgery”
OR “Ablation” OR “Catheter ablation” OR “Nursing
Practice” OR “Gait”)) NOT (TX “Students”)
Manufacturers’/generic names not
recognised. NOT “Catheter” OR
“Surgery” OR “Ablation” OR
“Catheter ablation” OR “Nursing
Practice” NOT “Students”
Google scholar
(wearable device)
ECG EKG Alive OR Cor OR Zoe OR Patch OR Scanadu
OR Scout OR Perminova OR CoVa OR necklace OR
Kardia OR ECG OR Necklace OR Cardio OR Analytics
OR Heal OR Force OR Smart OR Cardio OR Beurer OR
ME80 OR Beurer OR PM2 “wearable device”
Excluded patents
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Table 2. Cont.
Database Search Term Used Adaptions
Google scholar
(wearable technology)
ECG EKG Alive OR Cor OR Zoe OR Patch OR Scanadu
OR Scout OR Perminova OR CoVa OR necklace OR
Kardia OR ECG OR Necklace OR Cardio OR Analytics
OR Heal OR Force OR Smart OR Cardio OR Beurer OR
ME80 OR Beurer OR PM2 “wearable technology”
Excluded patents
PubMed
Palpitations OR Arrhythmia OR Atrial Fibrillation And
(ECG) AND (EKG) OR Wearable technologies OR
Wearable devices)) AND (Alive Cor OR Zoe Patch OR
Scanadu Scout OR Perminova CoVa necklace OR Kardia
OR ECG Necklace OR Cardio Analytics OR Heal Force
OR Smart Cardio OR Beurer ME80 OR Beurer PM25 OR
Prince 180B OR Cardea SOLO OR Spyder Pro OR Spyder
Personal OR MiCor A100)) NOT (sport AND
algorithms))
AND NOT sport AND algorithms
PubMed MESH
Wearable devices OR Wearable technologies AND (ECG
OR EKG) AND (Palpitations OR Arrhythmia OR Atrial
Fibrillation)
Manufacturers’/generic names not
recognised. AND NOT sport AND
algorithms
Scopus
Palpitations OR Arrhythmia OR Atrial Fibrillation And
{ECG} AND {EKG} OR Wearable* AND techonolo* OR
device AND NOT algorithms
Manufacturers’/generic names not
used Use wildcard* AND NOT
algorithms
Scopus
Alive Cor” OR “Zoe Patch” OR “Scanadu Scout” OR
“Perminova CoVa Necklace” OR “QardioCore” OR
“Kardia” OR “ECG Necklace” OR “Cardio Analytics” OR
“Heal Force” OR “Smart Cardio” Or “ChoiceMMed” OR
“Beurer ME80” OR “Beurer PM25” OR “Zodore” OR
“Prince 180B” OR “Cardea SOLO” OR “Spyder Pro” OR
“Spyder Personal” OR “MiCor A100”)
Dropped: “Palpitations” OR
“Arrhythmia” OR “Atrial
Fibrillation” AND “ECG” OR
“EKG”
5. Limitations
One of the limitations of this scoping review is that each database requires its own set of limiters.
Consequently, each database search is slightly different as demonstrated in Table 3. The database
searches did not identify the papers of Hendrikx et al. [13], Usadel et al. [14] and Dahlqvist et al. [15]
that are available via the Zenicor website [59]. These papers were published in April and May 2018
and therefore outside of the time period of this scoping literature review. Furthermore, these papers
did not fit the inclusion criteria because their primary area of investigation centred on the diagnosis
and treatment of stroke patients. Although the Dahlqvist et al. [15] paper fits the inclusion criteria,
the authors decided not to include it in Table 2 given that it did not appear in the search period.
Moreover, the Dahlqvist et al. [13] study did not fit the >18 age inclusion criteria of this scoping review
as participants in the respective study were children aged between 5 and 17 years old. Another paper
was excluded because it was published in Swedish [60] and consequently failed the English language
inclusion criterion.
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Table 3. Summary of articles (N = 9) included for this scoping review.
1st Author Year
Country Objectives Participants Study Design Assessment(s) Technology Main Findings
Aronsson et al. [40]
2015
Sweden
To estimate the cost
effectiveness of 2
weeks of intermittent
screening for
asymptomatic atrial
fibrillation (AF) in
75/76-year-old
individuals.
n = 25,415
Aged 75–76 years
Female 55.9%
Observational Cohort
study
In total, 30-s
recordings taken
twice daily, or when
symptoms of
palpitations for 2
weeks.
Zenicor EKG device
With the use of a decision analytic
simulation model, it has been shown
that screening for asymptomatic AF in
75/76-year-old individuals is cost
effective.
Doliwa, Rosenqvist,
and Frykman [41]
2012
Sweden
To compare short
intermittent heart
rhythm recording
with or without
symptoms with
continuous ECG
recordings for 30 days,
with two registrations
of 10 s per day.
n = 22
Aged 46–77 years
Females 27%
Median age 63 years
Experimental study,
randomised
controlled blinded
trial
Recordings were
taken twice daily;
once in the morning
and once in the
evening for a 30-day
period. Participants
were asked to record
when experiencing
arrhythmia
symptoms (recorded
as symptomatic).
Zenicor EKG device
AF episodes were diagnosed in 18 (82%)
patients compared with seven (32%)
patients using continuous ECG, (p =
0.001. Short-term ECG registrations over
extended periods of time seem to be a
more sensitive tool, compared with
short continuous ECG recordings, for
the detection of AF episodes.
Boudreau et al. [42]
2017
USA
To determine the
validity of eight
monitors for Heart
Rate (HR) compared
with an ECG and
seven monitors for
Energy Expenditure
(EE) compared with a
metabolic analyser
during graded cycling
and resistance
exercise.
n = 50
Aged 18–35 years
Female n = 28 (56%)
Mean age 22.71 ± 2.99
Experimental
comparative study
Session 1: Performed
a graded exercise test
on a cycle ergometer.
Session 2: Performed
a graded exercise test
of four different
strength training
exercises on a
resistance exercise
machine. Repeated 3
days later in the
laboratory.
Exclusion:
Cardiovascular
disease or
musculoskeletal
injury in the last 6
months.
Apple Watch Series 2,
Fitbit Blaze, Fitbit
Charge 2, Polar H7,
Polar A360, Garmin
Vivosmart HR,
TomTom Touch, and
Bose SoundSport
Pulse (BSP)
headphones
This study revealed that both HR and EE
differed among the eight wearable
devices during both cycling and
resistance exercise and had varying
levels of validity when compared with a
six-lead ECG and metabolic analyser. It
was also observed that HR measures
from wearable devices were more
accurate at rest and lower exercise
intensities than at higher intensities.
Among tested devices, HR accuracy, as
reflected by intraclass correlation and
MAPE values, was highest in the PH7,
BSP, and AWS2. The PH7 and AWS2 also
proved to provide more accurate caloric
estimations than other devices. HR from
wearable devices differed at different
exercise intensities; EE estimates from
wearable devices were inaccurate.
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1st Author Year
Country Objectives Participants Study Design Assessment(s) Technology Main Findings
Evans et al. [43] 2017
Kenya
To examine the
feasibility of using
mobile ECG
recording technology
to detect AF.
n = 50
Mean age 54.3 ± 20.5.
Females 66%
Prospective
observational study
Of 2-week duration.
In a rural community.
Health practitioners
(physicians, clinical
officers, nurse)
completed a
self-assessment of a
4-item scale relating
to ICT access,
knowledge/interpretation
of results and
perception of AF in
the community.
AliveCor Kardia
Mobile ECG device
ECG tracings of four of the 50 patients
who completed the study showed AF
(8% AF yield), and none had been
previously diagnosed with AF. Using
mobile ECG technology in screening for
AF in low-resource settings is feasible
and can detect a significant proportion
of AF cases that will otherwise go
undiagnosed. Further study is needed to
examine the cost effectiveness of this
approach for the detection of AF and its
effect on reducing the risk of stroke in
developing countries.
Haberman et al. [26]
2015
USA
Compare the
standard 12-lead ECG
to the smartphone
ECG in healthy young
adults, elite athletes,
and cardiology clinic
patients. Accuracy for
determining baseline
ECG intervals and
rate and rhythm was
assessed.
n = 335
Mean age 35 ± 20
Female 51%
Experimental
comparative study
Using an iPhone case
or iPad, 30-s lead
iECG waveforms
were obtained.
Standard 12-lead
ECGs were acquired
immediately after the
smartphone tracing
was obtained.
De-identified ECGs
were interpreted by
automated algorithms
and adjudicated by
two board-certified
electrophysiologists
AliveCor device (30-s
ECG wireless
reading). Patients
trained over 1–2 min
to take their own
readings
This study provides evidence that
wireless ECG devices can be used on a
large scale to detect rate, conduction
intervals and AF. Incorporation of
automated discrimination, with
enhanced smartphone features with
notification capability and decision
support. Both smartphone and standard
ECGs detected atrial rate and rhythm,
AV block, and QRS delay with equal
accuracy. Sensitivities ranged from 72%
(QRS delay) to 94% (atrial fibrillation).
Specificities were all above 94% for both
modalities.
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Country Objectives Participants Study Design Assessment(s) Technology Main Findings
Hickey et al. [44] 2016
USA
The primary aims of
the iHEART study are
to: (1) document AF
using real-time ECG
capture; (2) evaluate
the impact on AF
treatment and
Quality-Adjusted Life
Years (QALYs); and
(3) evaluate the
effectiveness of text
messaging on AF
knowledge and
promoting proactive
self-management of
multiple chronic
conditions
n = 300
Aged > 18 years
Study protocol,
observational study.
Single-centre
prospective
ECG reading taken at
baseline. Complete all
questionnaires at
baseline and at 6
months.
Questionnaires
included the Atrial
Fibrillation
Knowledge Scale, the
Canadian
Cardiovascular
Society Severity in
Atrial Fibrillation
scale, the Atrial
Fibrillation Effect on
Quality of Life, the
Control Attitudes
Scale-Revised, the
Morisky 4-item
Self-Report Measure
of Medication-Taking
Behaviour, the
Self-Efficacy for
Appropriate
Medication Use Scale,
the Short Form Health
Survey, European
Questionnaire 5
Dimensions, the
Patient Health
Questionnaire, and
the State Trait Anxiety
Inventory.
iPhone, AliveCor
Mobile ECG Kardia
app
This will be the first study to investigate
the utility of a mobile health intervention
in a “real world” setting. We will
evaluate the ability of the iHEART
intervention to improve the detection
and treatment of recurrent atrial
fibrillation and assess the intervention’s
impact on improving clinical outcomes,
quality of life, quality-adjusted life-years
and disease-specific knowledge.
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Halcox et al. [45] 2017
UK
n = 1001,
Mean age 72.6 ± 5.4
Females 53.34%
Experimental study
Baseline
characteristics.
Participant experience
survey (completed at
the end of the study).
Questions included
anxiety about their
heart rhythm
problems, more likely
to visit their doctor, or
prefer to switch to a
study group
(responses reported
via a 10-point visual
analogue scale).
iECG patients were
asked about ease of
use, restriction of
activities, anxiety,
concern about data
security and a general
satisfaction with the
device (via 5-point
Likert scale).
Health economics
were estimated from
the UK National
Health Service (NHS)
and personal social
services, using data
from the study
activity and relevant
costs.
AliveCor Kardia
device
Screening with twice-weekly single-lead
iECG with remote interpretation in
ambulatory patients ≥65 years of age at
increased risk of stroke is significantly
more likely to identify incident AF than
RC over a 12-month period. This
approach is also highly acceptable to this
group of patients, supporting further
evaluation in an appropriately powered,
event-driven clinical trial.
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McManus et al. [46]
2016
USA
To test whether an
enhanced smartphone
app for AF detection
can discriminate
between sinus rhythm
(SR), AF, premature
atrial contractions
(PACs), and
premature ventricular
contractions (PVCs).
AF—n = 98
65.9 ± 12.2
Male—n = 70 (71.4%)
White n = 91(92.9)
PAC—n = 15
73.1 ± 5.9
Male—n = 11 (73.3%)
White n = 14(93.3)
PVC—n = 15
62.8 ± 13.8
Male—n = 9 (60%)
White n = 13(86.7)
Sinus Rhythm—n =
91
66 ± 11.9
Male—n = 63 (69.2%)
White n = 86(94.5)
Experimental study
Analysis of 219 2-min
pulse recordings.
Usability
questionnaire to
sub-group of ns = 65
app users. Examined
the sensitivity,
specificity, and
predictive accuracy of
the app for AF, PAC,
and PVC
discrimination from
sinus rhythm using
the 12-lead EKG or
3-lead telemetry as
the gold standard.
PULSE-SMART
prototype App used
via the iPhone 4S
The smartphone-based app
demonstrated excellent sensitivity
(0.970), specificity (0.935), and accuracy
(0.951) for real-time identification of an
irregular pulse during AF. The app also
showed good accuracy for PAC (0.955)
and PVC discrimination (0.960). The
vast majority of surveyed app users
(83%) reported that it was “useful” and
“not complex” to use.
Turakhia et al. 2015a
[47]
USA
To detect silent AF in
asymptomatic
patients with known
risk factors through
screening for AF
using continuous
ambulatory ECG.
n = 75, Mean age 69 ±
8.0 years.
Male only
Observational study,
single centre
Records up to 14 days
of monitoring on a
single vector.
Participants press the
symptomatic trigger
on the device if
symptoms presented.
Patient diary,
detailing symptoms.
Baseline
characteristics:
demographics,
medical history, ECG
parameters, health
behaviours were
abstract from patient
medical record by two
trained investigators.
Zio wearable
patch-based device
AF was detected in four subjects (5.3%;
AF burden 28–48%). Atrial tachycardia
(AT) was present in 67% (≥4 beats), 44%
(≥8 beats), and 6.7% (≥60 s) of subjects.
The combined diagnostic yield of
sustained AT/AF was 11%. In subjects
without sustained AT/AF, 11 (16%) had
≥30 supraventricular ectopic complexes
per hour Outpatient extended ECG
screening for asymptomatic AF is
feasible, with AF identified in one in 20
subjects and sustained AT/AF identified
in one in nine subjects, respectively. We
also found a high prevalence of
asymptomatic AT and frequent
supraventricular ectopic complexes,
which may be relevant to development
of AF or stroke.
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6. Future Research
Based on the findings of this review, the authors propose several areas for furthering and expanding
this research:
1. Future work may wish to consider undertaking a systematic review in order to synthesise existing
and recently published work. This systematic review could include development features,
accuracy, algorithms, utility and reproducibility, in addition to diagnostics and user/patient
experience(s).
2. Following the work of Evans et al. [40], clinicians and researchers alike should consider exploring
the use of mobile ECG devices from the standpoint of health practitioners working in the delivery
of primary and community care.
3. Implementing and conducting qualitative data collection in future studies would provide a
greater insight and understanding of the needs, apprehensions, and expectations of patients and
primary care practitioners. Simultaneously, this would provide the opportunity to examine the
role of patient’s and support networks. Evans et al. [40] illustrated the potential opportunities for
mobile ECG monitoring in low, middle income countries (LMICs), and by their approach has the
potential to offer substantial changes in developed and developing regions.
4. Future investigations should explore the adherence and adoption of mobile ECG devices, learning
from previous health, gerontological and ICT studies [61–68]. Existing research in different fields
has demonstrated how technology has been used and evaluated by community dwelling adults
living in different geographic locations. Understanding people’s motivations and behaviour
in relation to technology would significantly support future work in this field. In addition,
the impact of technology efficacy by health practitioners on service delivery could be assessed.
a. Privacy and security issues and concerns surrounding data need to be addressed from
a multi-disciplinary standpoint. Further work is needed to explore the use of wearable
devices from a clinical environment and conducting qualitative data to gain an in-depth
insight into the concerns of patients, support networks and practitioners.
5. Future studies should determine the exact cost effectiveness of deploying mobile ECG devices
with the aim of providing evidence to health care strategists, governments and managers of the
benefits of this form of technology in the community. Such studies could have a significant impact
in the care pathways following the detection of AR and AF.
6. To ascertain how mobile ECG devices could affect the delivery of primary care, we suggest that a
large-scale feasibility study, encompassing variable populations (i.e., age range, ethnicity and
socio economic), should be conducted to provide results to different actors (i.e., government,
health care practitioners, health care strategists, researchers, patients and support networks).
It is important that such studies include as full a range of actors as possible from primary care
physicians, cardiologists, patients, lay people, patients’ support networks, health organizations
(i.e., NICE), and government funding agencies.
7. Future scoping reviews should follow the recent extension to the existing PRISMA protocol—the
PRISMA Extension for Scoping Reviews (PRISMA-ScR) [68].
The findings of this scoping review contribute to the fields of primary care, medicine and wearable
devices. Nonetheless, ECG wearable devices are directly available to consumers via retail outlets
and online websites. With this in mind, there is a risk to users who choose to purchase devices from
online stores or directly from suppliers or manufacturer’s website. Users may not fully understand
the recordings or misunderstand the information presented to them. For example, the accurate
interpretation of output statistics and the recognition of any false positives and false negatives. Thus,
this leads to a myriad of issues for clinicians, users, and carers and may have health consequences
for individuals and cost implications for service providers. These devices while readily available on
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the market have not necessarily gone through the process of being categorised as medical devices.
This issue was raised by Marston and Smith [65,66] concerning the delivery of physiotherapy via
videogame consoles. Consequently, Marston and Smith [65,66] argued for the need and requirement of
videogame consoles to undergo some form of official categorization and approval rating. While there
are worldwide videogame classifications [66], this is not the case for wearable devices and in particular
mobile ECG devices. We argue for a requirement for the manufacturers of mobile ECG devices to
gain FDA and European Medicines Agency (EMA) approval. However, as noted by Mantovani and
Bocos [67] and Wiersinga [69], gaining FDA and EMA approval is not a straightforward process and,
given the phenomenal developments within this domain, applying for medical device classification
could be very time consuming. However, Wiersinga [69] discusses in depth the regulation processes
for medical devices from the standpoint of industry and proposed recommendations for best practice.
7. Conclusions
This review is distinctive because it demonstrates positive trends to using and deploying mobile
ECG devices across different environmental settings and populations. With global populations set to
increase over the coming decades, the need to identify alternative solutions to facilitate and ensure
primary care providers are able to deliver cost-effective health care is crucial, for both the service
provider and the patient [9]. Detecting and diagnosing AR/AF using mobile ECG devices would
reduce the risk of morbidity and associated health implications such as stroke or mortality [5–7,70].
Based on the evidence displayed in this review, the authors believe substantial work is warranted
at both a national and international scale with a view to supporting primary care providers to deliver
high levels of care at a low cost to the service provider. This, in turn will alleviate patient anxiety,
risk of morbidity and mortality. In addition, it would positively impact on national and international
guidelines concerning pathways to care.
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